GSK preps for vaccine R&D expansion, 200 hires for new global hub
A year and a half after GlaxoSmithKline set in motion its big flip with Novartis, trading cancer drugs for vaccines, the UK pharma giant has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
